Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
复制标题
DOI：
10.3390/cancers13143466
复制
发表时间：
2021-07-11
期刊：
影响因子：
5.2
通讯作者：
Jean C
中科院分区：
文献类型：
--
作者：
Belhabib I;Zaghdoudi S;Lac C;Bousquet C;Jean C
在实体癌中观察到的基质修饰现在被认为是癌症进展的关键事件，并且是潜在的治疗或诊断靶点。最近对细胞外基质（ECM）在癌症中的多种但复杂的作用以及癌症相关成纤维细胞（CAF）多样性的认识彻底改变了该领域，并提出了创新但具有挑战性的问题。在这篇综述中，我们总结了ECM在癌症进展中的作用的最新知识，讨论了潜在的使用这种基质促肿瘤修饰作为治疗或诊断目标，最后，讨论的好处，失望，甚至失败，最近报道的基质靶向策略。实体癌进展取决于肿瘤细胞特征和与其微环境的促肿瘤串扰。基质修饰，如成纤维细胞活化成癌症相关成纤维细胞（CAF）和细胞外基质（ECM）重塑，现在被认为是癌症进展的关键事件，并作为潜在的治疗或诊断目标。最近对ECM在癌症中的关键、复杂和多重作用以及CAF多样性的认识，彻底改变了该领域，并提出了创新但具有挑战性的问题。在这里，我们迅速提出了CAF异质性与其在癌症中观察到的特定ECM重塑特征的联系，然后研究了这种ECM修饰对肿瘤进展的每一种影响（存活、血管生成、转移前小生境、化疗抗性等），以及患者预后。最后，基于临床前研究和最近从临床试验中获得的结果，我们强调了关键机制或蛋白质，或可能被用作潜在的治疗或诊断靶点，我们报告和讨论的好处，失望，甚至失败，最近报道的基质靶向策略。
Stroma modifications observed in solid cancer are now recognized as critical events for cancer progression and as potential therapeutic or diagnostic targets. The recent appreciation of multiple but complex roles of the extracellular matrix (ECM) in cancer, and of the cancer-associated fibroblast (CAF) diversity, has revolutionized the field and raised innovative but challenging questions. In this review, we summarize the latest knowledge regarding the role of the ECM in cancer progression, discuss the potential use of such stromal pro-tumoral modifications as therapeutic or diagnostic targets, and, finally, discuss benefits, disappointments, or even failures, of recently reported stroma-targeting strategies. Solid cancer progression is dictated by neoplastic cell features and pro-tumoral crosstalks with their microenvironment. Stroma modifications, such as fibroblast activation into cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM) remodeling, are now recognized as critical events for cancer progression and as potential therapeutic or diagnostic targets. The recent appreciation of the key, complex and multiple roles of the ECM in cancer and of the CAF diversity, has revolutionized the field and raised innovative but challenging questions. Here, we rapidly present CAF heterogeneity in link with their specific ECM remodeling features observed in cancer, before developing each of the impacts of such ECM modifications on tumor progression (survival, angiogenesis, pre-metastatic niche, chemoresistance, etc.), and on patient prognosis. Finally, based on preclinical studies and recent results obtained from clinical trials, we highlight key mechanisms or proteins that are, or may be, used as potential therapeutic or diagnostic targets, and we report and discuss benefits, disappointments, or even failures, of recently reported stroma-targeting strategies.
登录
查看更多内容
影响因子：
16.1
作者：
Au JL;Yeung BZ;Wientjes MG;Lu Z;Wientjes MG
通讯作者：
Wientjes MG
影响因子：
3.4
作者：
Aung, Aereas;Seo, Young N.;Varghese, Shyni
通讯作者：
Varghese, Shyni
影响因子：
3.7
作者：
Biasi F;Guina T;Maina M;Nano M;Falcone A;Aroasio E;Saracco GM;Papotti M;Leonarduzzi G;Poli G
通讯作者：
Poli G
影响因子：
11.5
作者：
Armstrong, T;Packham, G;Iredale, JP
通讯作者：
Iredale, JP
DOI：
10.1634/theoncologist.2017-0024
发表时间：
2017-03
期刊：
The oncologist
影响因子：
--
作者：
Benson AB 3rd;Wainberg ZA;Hecht JR;Vyushkov D;Dong H;Bendell J;Kudrik F
通讯作者：
Kudrik F